CPNE5 and blood vessel leaks in sepsis-related heart failure
Official title: CPNE5 in Cardiovascular Barrier Dysfunction and Septic Cardiomyopathy
Funded at University of Cincinnati · NIH-11419035 · Data updated 2026-11-12
This grant studies a protein called CPNE5 and how it affects blood vessel leaks that can lead to heart problems during severe infections like sepsis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | August 1, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $753,539 |
| NIH project number | 1R01HL187149-01 |
| Project ID | NIH-11419035 on NIH RePORTER |
Who could benefit from this research
✓Could help
No patient enrollment is described in this grant; however, findings may translate to human sepsis patients in future trials.
✕Less likely to help
The current grant does not involve recruiting patients or directly testing therapies in people.
What this research studies
If funded, researchers will use a CPNE5-knockout mouse model to understand how low CPNE5 levels contribute to vascular leakage and heart dysfunction in sepsis. They aim to connect CPNE5 presence to the strength of the endothelial barrier and to how the heart is affected during septic illness. The study will combine animal experiments with lab work to explore mechanisms and potential therapeutic angles. Results could point to new ways to protect the heart and blood vessels in patients with sepsis.
Why it matters
Potential benefit: Better understanding of CPNE5 could lead to new strategies to prevent heart damage and improve survival in sepsis patients.
How similar studies have gone: Preclinical studies in animals suggest CPNE5 influences vascular leakage and heart function during sepsis, but translation to humans remains to be proven.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Fan, Guo-Chang — University of Cincinnati
- Study coordinator: Fan, Guo-Chang
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.